Precigen's third quarter delivered nearly every operating milestone a young launch story needs except the headline beat. The company earned $0.08 per diluted share on revenue of $74.15 million. That fell short of the $0.09 consensus by 11.1% and missed the $75.43 million revenue estimate by 1.7%. The year-over-year comparisons are enormous: earnings grew 172.7% and revenue rose 2437.6%. Net income of $35.8 million replaced a loss of $325.3 million attributable to common shareholders a year ago, a period burdened by a $111.5 million warrant charge and a $179.0 million deemed dividend. Those comparisons mostly reflect PAPZIMEOS going from zero to a full commercial quarter. The more relevant comparison is sequential, and that is where the central tension sits. PAPZIMEOS net revenue rose 37% to $72.9 million, but that follows roughly 146% sequential growth in the second quarter, while a competitor is now preparing to enter the market.
The quality of the quarter is mixed. On the positive side, Precigen generated $11.9 million of operating cash flow. That is a full quarter ahead of its long-standing guidance for cash flow breakeven by year-end. Cash and investments rose to $51.0 million from $38.7 million. Management stated that no additional capital raise is needed and noted $25 million of undrawn debt capacity. For a company that carried an accumulated deficit of roughly $2.3 billion, that is a genuine shift. However, the gap between $35.8 million of net income and $11.9 million of operating cash flow deserves scrutiny. Trade receivables climbed to $96.5 million from $71.9 million last quarter and from just $3.9 million at year-end. Some of that build is natural for a ramping specialty product, but it is worth watching. Gross margin also slipped to 91% from 95% as low-cost pre-launch inventory ran out. Management framed that as normalization toward its high-80s to low-90s steady-state target. Investors should note one more detail: GAAP diluted EPS of $0.08 sits below basic EPS of $0.10 because of a diluted share count of about 421 million.
The demand indicators kept moving in the right direction. Well over 500 patients have started treatment, up from more than 200 at the time of the second-quarter call. Completions now exceed 300, and hub registrations passed 600. Payer coverage spans about 315 million lives, nearly all insured Americans, and a permanent J-code has been in place since April. Management also highlighted uptake among patients with fewer than three surgeries in the prior year. That suggests use is broadening beyond the most severe cases, and launch-to-date revenue has reached roughly $151 million. Still, there was no formal fourth-quarter guidance, and leading indicators were described only qualitatively.
What changed most on the call was the competitive framing. Inovio has received conditional FDA approval for a rival RRP therapy and is expected to launch in the new year. As a result, much of the call shifted from celebrating launch momentum to defending leadership. Management emphasized PAPZIMEOS's 51% complete response rate, full rather than conditional approval, absence of serious treatment-related adverse events, and device-free subcutaneous dosing. It also addressed competitive messaging around surgery during the dosing window. Notably, the seven-year exclusivity point highlighted last quarter was not repeated. On the catalyst side, the FDA granted Platform Technology Designation to AdenoVerse, and five-year durability data were presented. The redosing trial is enrolling, the EMA is reviewing the European application, and management is evaluating inbound ex-US partnership interest. An upcoming R&D Day will feature new Phase 2 PRGN-2009 data.
The market had already been pricing in the competitive threat. Shares hit a 52-week high of $8.98 on September 30 but entered the report at $5.25, down 41.5% from that peak. That is 25.2% below the open following the August report and only 7% above the inter-earnings low of $4.91 set November 2. The stock is sitting essentially on its 200-day moving average of $5.27. Investor sentiment deteriorated meaningfully, sliding from roughly neutral at -0.05 to -0.28. Sequential growth and momentum trend readings remain positive, while AVWAP is negative, a pattern consistent with a stock that has retreated sharply despite still-improving fundamentals.
The bottom line is that Precigen executed its launch well, reaching profitability and self-funding status faster than promised. However, the narrow miss, slowing sequential growth, a margin step-down, and swelling receivables arrive just as a competitor prepares to launch. Bears have legitimate ammunition. With the stock already down sharply and sentiment soured, the next few quarters of patient starts and pricing resilience against Inovio will matter more than this quarter's penny shortfall.